BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it has completed its Type C meeting regarding intravenous (i.v.) peramivir with the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE